Published in Lancet Oncol on August 19, 2014
TIGER PRO-Active - Daily Activity, Sleep and Neurocognitive Functioning Study | NCT04717739
Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro Oncol (2015) 2.21
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer (2015) 1.43
Does cilengitide deserve another chance? Lancet Oncol (2014) 1.11
Advances and challenges in the molecular biology and treatment of glioblastoma-is there any hope for the future? Ann Transl Med (2015) 1.04
Toward precision medicine in glioblastoma: the promise and the challenges. Neuro Oncol (2015) 0.98
The challenges and the promise of molecular targeted therapy in malignant gliomas. Neoplasia (2015) 0.96
Advances in the molecular genetics of gliomas - implications for classification and therapy. Nat Rev Clin Oncol (2016) 0.96
What next for newly diagnosed glioblastoma? Future Oncol (2015) 0.94
Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter-still a dilemma? Neuro Oncol (2015) 0.93
A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma. Neuro Oncol (2015) 0.88
Patient-derived glioblastoma stem cells are killed by CD133-specific CAR T cells but induce the T cell aging marker CD57. Oncotarget (2015) 0.88
Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review). Int J Oncol (2015) 0.87
Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial. Neuro Oncol (2016) 0.85
Corticosteroids compromise survival in glioblastoma. Brain (2016) 0.84
Outcome in unresectable glioblastoma: MGMT promoter methylation makes the difference. J Neurol (2016) 0.83
Development of targeted therapies in treatment of glioblastoma. Cancer Biol Med (2015) 0.83
Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma. J Natl Cancer Inst (2015) 0.83
Point/counterpoint: randomized versus single-arm phase II clinical trials for patients with newly diagnosed glioblastoma. Neuro Oncol (2017) 0.82
β1 Integrins as Therapeutic Targets to Disrupt Hallmarks of Cancer. Front Pharmacol (2015) 0.82
The development of dendritic cell vaccine-based immunotherapies for glioblastoma. Semin Immunopathol (2017) 0.82
ITGAV and ITGA5 diversely regulate proliferation and adipogenic differentiation of human adipose derived stem cells. Sci Rep (2016) 0.82
Advances in the treatment of newly diagnosed glioblastoma. BMC Med (2015) 0.82
The complexity of integrins in cancer and new scopes for therapeutic targeting. Br J Cancer (2016) 0.81
Tumor angiogenesis in the absence of fibronectin or its cognate integrin receptors. PLoS One (2015) 0.81
The aryl hydrocarbon receptor links integrin signaling to the TGF-β pathway. Oncogene (2015) 0.81
Glioblastomas Require Integrin αvβ3/PAK4 Signaling to Escape Senescence. Cancer Res (2015) 0.80
Peritumoral edema shown by MRI predicts poor clinical outcome in glioblastoma. World J Surg Oncol (2015) 0.80
Concurrent therapy to enhance radiotherapeutic outcomes in glioblastoma. Ann Transl Med (2016) 0.80
Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. J Clin Oncol (2016) 0.80
Cilengitide in glioblastoma: when did it fail? Lancet Oncol (2014) 0.80
Anti-angiogenic alternatives to VEGF blockade. Clin Exp Metastasis (2015) 0.79
Integrin α5β1 and p53 convergent pathways in the control of anti-apoptotic proteins PEA-15 and survivin in high-grade glioma. Cell Death Differ (2015) 0.79
End of the road: confounding results of the CORE trial terminate the arduous journey of cilengitide for glioblastoma. Neuro Oncol (2015) 0.79
Impact of waiting time after surgery and overall time of postoperative radiochemotherapy on treatment outcome in glioblastoma multiforme. Radiat Oncol (2015) 0.79
Guidance of Signaling Activations by Cadherins and Integrins in Epithelial Ovarian Cancer Cells. Int J Mol Sci (2016) 0.78
TSPO PET for glioma imaging using the novel ligand (18)F-GE-180: first results in patients with glioblastoma. Eur J Nucl Med Mol Imaging (2017) 0.78
A Comprehensive Evaluation of the Activity and Selectivity Profile of Ligands for RGD-binding Integrins. Sci Rep (2017) 0.78
TTFields: where does all the skepticism come from? Neuro Oncol (2016) 0.78
Integrin β3 inhibition is a therapeutic strategy for supravalvular aortic stenosis. J Exp Med (2016) 0.78
Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cells. Nat Rev Clin Oncol (2017) 0.78
Tumor treating fields: a novel treatment modality and its use in brain tumors. Neuro Oncol (2016) 0.78
A niche role for periostin and macrophages in glioblastoma. Nat Cell Biol (2015) 0.77
Therapeutic approach beyond conventional temozolomide for newly diagnosed glioblastoma: Review of the present evidence and future direction. Indian J Med Paediatr Oncol (2016) 0.77
Ex vivo engineered immune organoids for controlled germinal center reactions. Biomaterials (2015) 0.77
Long-term survival in glioblastoma: methyl guanine methyl transferase (MGMT) promoter methylation as independent favourable prognostic factor. Radiol Oncol (2016) 0.77
Metformin inhibits proliferation and migration of glioblastoma cells independently of TGF-β2. Cell Cycle (2016) 0.77
Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial. Oncotarget (2016) 0.77
Current status and future directions of anti-angiogenic therapy for gliomas. Neuro Oncol (2015) 0.77
Antagonizing Integrin β3 Increases Immunosuppression in Cancer. Cancer Res (2016) 0.77
Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium. J Immunol Res (2016) 0.77
Phase I trial of dovitinib (TKI258) in recurrent glioblastoma. J Cancer Res Clin Oncol (2016) 0.77
Stromal Modulators of TGF-β in Cancer. J Clin Med (2017) 0.76
Novel synthetic cyclic integrin αvβ3 binding peptide ALOS4: Antitumor activity in mouse melanoma models. Oncotarget (2016) 0.76
Anti-thrombotic agents derived from snake venom proteins. Thromb J (2016) 0.76
Glioblastoma multiforme: emerging treatments and stratification markers beyond new drugs. Br J Radiol (2015) 0.76
Hypoxia Selectively Enhances Integrin α5β1 Receptor Expression in Breast Cancer to Promote Metastasis. Mol Cancer Res (2017) 0.76
Pharmacotherapy of Glioblastoma: Established Treatments and Emerging Concepts. CNS Drugs (2017) 0.76
Can Integrin Agonists Have Cards to Play against Cancer? A Literature Survey of Small Molecules Integrin Activators. Cancers (Basel) (2017) 0.76
A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors. Invest New Drugs (2016) 0.75
Indian data on central nervous tumors: A summary of published work. South Asian J Cancer (2016) 0.75
Impact of Including Peritumoral Edema in Radiotherapy Target Volume on Patterns of Failure in Glioblastoma following Temozolomide-based Chemoradiotherapy. Sci Rep (2017) 0.75
Identification of an Endogenously Generated Cryptic Collagen Epitope (XL313) That May Selectively Regulate Angiogenesis by an Integrin Yes-associated Protein (YAP) Mechano-transduction Pathway. J Biol Chem (2015) 0.75
Tension in Cancer. Int J Mol Sci (2016) 0.75
Stattic and metformin inhibit brain tumor initiating cells by reducing STAT3-phosphorylation. Oncotarget (2016) 0.75
Targeting hyperactivated DNA-PKcs by KU0060648 inhibits glioma progression and enhances temozolomide therapy via suppression of AKT signaling. Oncotarget (2016) 0.75
Milestones of the last 10 years: CNS cancer. Memo (2017) 0.75
The Effect of Stromal Integrin β3-Deficiency on Two Different Tumors in Mice. Cancers (Basel) (2016) 0.75
Factorial clinical trials: a new approach to phase II neuro-oncology studies. Neuro Oncol (2014) 0.75
Targeting αvβ3 and αvβ5 integrins inhibits pulmonary metastasis in an intratibial xenograft osteosarcoma mouse model. Oncotarget (2016) 0.75
Real-time near-infrared fluorescence imaging using cRGD-ZW800-1 for intraoperative visualization of multiple cancer types. Oncotarget (2017) 0.75
A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies. Invest New Drugs (2016) 0.75
Therapeutic Potential of Curcumin for the Treatment of Brain Tumors. Oxid Med Cell Longev (2016) 0.75
Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide. Clin Cancer Res (2015) 0.75
Molecular Imaging of Angiogenesis and Vascular Remodeling in Cardiovascular Pathology. J Clin Med (2016) 0.75
New Directions in Anti-Angiogenic Therapy for Glioblastoma. Neurotherapeutics (2017) 0.75
Systemic Delivery of Tumor-Targeted Bax-Derived Membrane-Active Peptides for the Treatment of Melanoma Tumors in a Humanized SCID Mouse Model. Mol Ther (2017) 0.75
Toward Personalized Targeted Therapeutics: An Overview. Neurotherapeutics (2017) 0.75
Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review. World J Surg Oncol (2016) 0.75
Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome. Oncotarget (2016) 0.75
The effect of antagonizing RGD-binding integrin activity in papillary thyroid cancer cell lines. Onco Targets Ther (2016) 0.75
Creating clinical trial designs that incorporate clinical outcome assessments. Neuro Oncol (2016) 0.75
Methylation of MGMT Is Associated with Poor Prognosis in Patients with Stage III Duodenal Adenocarcinoma. PLoS One (2016) 0.75
MGMT-Methylated Alleles Are Distributed Heterogeneously Within Glioma Samples Irrespective of IDH Status and Chromosome 10q Deletion. J Neuropathol Exp Neurol (2016) 0.75
Dose-escalated intensity-modulated radiotherapy and irradiation of subventricular zones in relation to tumor control outcomes of patients with glioblastoma multiforme. Onco Targets Ther (2016) 0.75
A network meta-analysis: the overall and progression-free survival of glioma patients treated by different chemotherapeutic interventions combined with radiation therapy (RT). Oncotarget (2016) 0.75
Acute Temporal Changes of MRI-Tracked Tumor Vascular Parameters after Combined Anti-angiogenic and Radiation Treatments in a Rat Glioma Model: Identifying Signatures of Synergism. Radiat Res (2016) 0.75
Insights into the Binding of Cyclic RGD Peptidomimetics to α5β1 Integrin by using Live-Cell NMR And Computational Studies. ChemistryOpen (2016) 0.75
Antiangiogenic mechanisms and factors in breast cancer treatment. J Carcinog (2016) 0.75
Integrins in the Spotlight of Cancer. Int J Mol Sci (2016) 0.75
Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in korea. Oncotarget (2016) 0.75
Pediatric Brain Tumors: Current Knowledge and Therapeutic Opportunities. J Pediatr Hematol Oncol (2016) 0.75
Does cilengitide deserve another chance?-Authors' reply. Lancet Oncol (2014) 0.75
Probing Membrane Receptor - Ligand Specificity with Surface- and Tip- Enhanced Raman Scattering. Anal Chem (2017) 0.75
How can we develop therapies for glioblastoma more efficiently? Randomized versus single-arm studies. Neuro Oncol (2017) 0.75
Potential of Integrin Inhibitors for Treating Ovarian Cancer: A Literature Review. Cancers (Basel) (2017) 0.75
Integrin αvβ3 Signaling in Tumor-Induced Bone Disease. Cancers (Basel) (2017) 0.75
Is the prognostic significance of O6-methylguanine- DNA methyltransferase promoter methylation equally important in glioblastomas of patients from different continents? A systematic review with meta-analysis. Cancer Manag Res (2017) 0.75
Inter-heterogeneity and intra-heterogeneity of αvβ3 in non-small cell lung cancer and small cell lung cancer patients as revealed by (68)Ga-RGD2 PET imaging. Eur J Nucl Med Mol Imaging (2017) 0.75
Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016. Eur J Cancer (2016) 0.95
Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer. Eur J Cancer (2005) 0.85
Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial. J Natl Cancer Inst (2017) 0.78
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol (2017) 0.77
Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome. Oncotarget (2016) 0.75
Does cilengitide deserve another chance?-Authors' reply. Lancet Oncol (2014) 0.75
Go, no-go decision making for phase 3 clinical trials: ACT IV revisited - Authors' reply. Lancet Oncol (2017) 0.75
Consensus Report From the Stockholm Pediatric Proton Therapy Conference. Int J Radiat Oncol Biol Phys (2016) 0.75
Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study. Cancer Chemother Pharmacol (2017) 0.75